Important Update for Myeloma Patients: Selinexor STORM Trials

Selinexor is an orally administered Selective Inhibitor of Nuclear Export, or SINE™, therapy for the treatment of multiple myeloma. Selinexor inhibits the transport of tumor suppressor proteins from the cell nucleus, where they detect cancerous DNA changes and induce cancer cell death. More than 900 patients have been treated with selinexor in phase I and phase II clinical trials and in an ongoing phase I clinical trial, Selinexor in combination with low-dose dexamethasone demonstrated favorable responses. To read more about the Selinexor STORM trials, please click HERE.
Source: International Myeloma Foundation - Category: Hematology Source Type: news